' Bad News ' : Adjuvant Denosumab Disappoints in Early Breast Cancer ' Bad News ' : Adjuvant Denosumab Disappoints in Early Breast Cancer

Adjuvant denosumab failed to show any clinical benefit on bone metastasis or disease recurrence in high-risk, early breast cancer in the phase 3 D-CARE trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news